



Figure S6. Properties of TRAIL-sensitizing CMS compound(s). (A) Both the CMS and the purified < 3 kDa fraction sensitize BJEL cells to comparable levels of TRAIL-induced apoptosis ($n \geq 4$, SEM, # $p > 0.1$). (B) CMS factor(s) responsible for sensitization to TRAIL is/are temperature-stable and retain(s) the ability to sensitize BJEL cells to apoptosis after freeze/thawing (left panel) or boiling (right panel). (C and D) CMS factor(s) responsible for sensitization retain(s) the ability to sensitize BJEL cells to TRAIL-induced apoptosis after a proteolytic enzyme treatment (C), while the same treatment led to degradation and loss of activity of a synthetic TRAIL peptide (D) (for the TRAIL peptide mimic see Pavet et al. 2010 Cancer Res 70, 1101).